Alector, Inc.

Stocks

ALEC

US0144421072

Market Closed - Nasdaq 01:30:00 25/09/2026 am IST			5-day change	1st Jan Change
1.920 ^USD	-4.95%		+3.78%	+23.08%

16/09	Novartis halts ALS drug development after mid-stage trial failure	RE
15/09	Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM

Transcript : Alector, Inc. - Special Call

Published on 05/05/2026 at 08:07 pm IST - Modified on 06/12/2026 at 09:33 pm IST

S&P Capital IQ

Presenter Speech
Pete Stavropoulos (Analysts)

Hello, everyone. I'm Pete Stavropoulos, biotech analyst at Cantor with another webinar on the blood-brain barrier crossing technologies. It's an exciting

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Alector, Inc.

16/09	Novartis halts ALS drug development after mid-stage trial failure	RE
15/09	Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM
15/09	Alector, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02:10 PM
07/08	Alector, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
09/07	Wall Street Ignores the Sirens
09/07	GSK adds Royal Philips' Chief Executive Jakobs to board	AN
09/07	Oil keeps markets on edge
09/07	UK Stocks-Factors to watch on July 9	RE
09/07	Alector and GSK partnership to end after dementia, Alzheimer's drug failures	RE
09/07	Alector, Inc. Announces Termination of Collaboration Agreement with Glaxo Wellcome UK Limited	CI
09/07	Alector LLC and Alector, Inc. Repay $10,428,827.77 Aggregate Principal Amount Of Loans Under Loan And Security Agreement With Hercules Capital, Inc	CI
08/05	Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05/05	Alector, Inc. - Special Call
30/04	Alector to discontinue phase 2 trial of nivisnebart	RE
30/04	Alector Inc Discontinues Phase 2 Progress-Ad Trial of Nivisnebart and Provides Pipeline Update	CI

Chart Alector, Inc.

Duration

Period

ALEC: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

More financial data

Ratings

More Ratings

EPS Estimates

Revisions to estimates